BPC-157 + TB-500 10+10mg: What the Higher-Mass Rung Changes
By UK Peptide Lab Research Team•19 September 2026•5 min read
Key Takeaways
- The 10+10mg vial is the same co-formulation as the 5+5mg rung at double the mass: 20mg of total peptide, identical chemistry, and the same approximate 3.5 to 1 molar ratio in favour of BPC-157.
- Ten milligrams of BPC-157 is roughly 7.0 µmol and ten milligrams of TB-500 roughly 2.0 µmol, because the 1419.53 g/mol to 4963.4 g/mol mass difference scales exactly as it did at 5+5mg.
- The higher mass buys fewer vials, fewer reconstitution events and one lot boundary for a given experiment; it costs a single in-use window committed to 20mg.
- No controlled study has tested the combination against either component alone, and the 2025 McGuire review identifies only three human pilot studies for BPC-157. In-vitro laboratory research use only.
What the 10+10mg Rung Is
The BPC-157 + TB-500 10+10mg vial is the higher-mass presentation of the blend already offered at 5+5mg. The chemistry is unchanged. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, 1419.53 g/mol; TB-500 is the synthetic 17-23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, CAS 77591-33-4, 4963.4 g/mol. What differs between rungs is quantity: 20mg of total peptide in one lyophilised vial instead of 10mg.
The Molar Arithmetic Is Unchanged
An equal-mass blend is not equimolar, and doubling the mass leaves the ratio untouched. Ten milligrams of BPC-157 is roughly 7.0 µmol and ten milligrams of TB-500 roughly 2.0 µmol, so this vial holds the same approximate 3.5 to 1 molar ratio in favour of BPC-157 as the 5+5mg rung. Mass-based and mole-based descriptions of the vial are not interchangeable.
What the Higher Mass Changes
The differences are bench-level rather than biological. A 10+10mg vial supplies twice the peptide per reconstitution, so a given total mass needs half the vials and one lot boundary instead of two across an experiment, and it permits a doubled working concentration at the same fill volume. The trade-off is symmetric: once reconstituted, 20mg sits behind a single in-use window, so lower-throughput designs may prefer the 5+5mg rung. The certificate must still resolve two species of very different mass.
The Science Behind the Blend
Both components sit among the most referenced peptides in cell migration, angiogenesis and tissue repair research. For BPC-157, Hsieh and colleagues (J Mol Med, 2017) reported VEGFR2 upregulation and internalisation in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reported increased focal adhesion kinase and paxillin phosphorylation in cultured rat tendon fibroblasts. For thymosin beta-4, Bock-Marquette and colleagues (Nature, 2004) reported migration and survival effects in cardiac injury models, and Philp and colleagues (Wound Repair Regen, 2003) found the actin-binding peptide LKKTETQ promoted dermal wound repair in diabetic and aged mice.
The Honest Position
No controlled study has tested this combination against either component alone, so combination-specific claims cannot be supported. The 2025 review by McGuire and colleagues (Curr Rev Musculoskelet Med) identifies only three human pilot studies for BPC-157, with no adequately powered randomised controlled trials. This guide therefore carries no dosing information, no human-use claims and no therapeutic promises. The blend is supplied as a convenience of format for in-vitro laboratory research only.
Handling at 20mg
Reconstitute with bacteriostatic water injected slowly down the inner glass wall, never onto the cake, then swirl gently until clear and colourless; do not shake or vortex, as agitation reduces recovery of intact TB-500. Store lyophilised vials at -20°C and reconstituted solution at 2-8°C, with single-use aliquots for longer storage. One reconstitution date governs both components; label every aliquot with fill volume, concentration and date.
Sourcing in the UK
UK Peptide Lab supplies BPC-157 + TB-500 10+10mg as lyophilised powder, supplier-tested under batch UKPL-9514 with per-component content verified, with the certificate published on the product page and independent third-party verification pending. Same-day dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. Purchasers must be 18 or over and confirm research-only use.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.
Frequently Asked Questions
What is the difference between the 10+10mg and 5+5mg vials?
The chemistry is identical and the mass is doubled. Both vials hold equal masses of BPC-157 and TB-500, both carry the same approximate 3.5 to 1 molar ratio in favour of BPC-157, and both are lyophilised powder. The 10+10mg vial puts 20mg of total peptide behind one reconstitution date instead of 10mg, which suits higher-throughput designs and costs flexibility in low-throughput ones.
Is the blend equimolar?
No. It is equal by mass and roughly 3.5 to 1 by moles. Ten milligrams of BPC-157 is approximately 7.0 µmol and ten milligrams of TB-500 approximately 2.0 µmol, because the molecular weights are 1419.53 g/mol and 4963.4 g/mol respectively.
How should the 10+10mg vial be reconstituted and stored?
Add bacteriostatic water slowly down the inner glass wall and swirl gently until clear and colourless; never shake or vortex. Store lyophilised vials at -20°C and reconstituted solution at 2-8°C, with single-use aliquots for longer storage. Research use only.
References
- [1] Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (2017). View →
- [2] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011). View →
- [3] Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004). View →
- [4] Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen (2003). View →
- [5] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med (2025). View →